• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Pfizer, in a rare COVID-19 setback, dumps Paxlovid's intravenous sibling in further...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 09, 2022 at 10:22: AM
via Add Pfizer to the long list of victims of ACTIV-3. While the Big Pharma has enjoyed unparalleled success in COVID-19, it was unable to buck the trend in the National Institutes of Health (NIH) study of hospitalized patients and has stopped development of Paxlovid’s intravenous sibling PF-07304814.

article source
 




Top Bottom
Back
Quote